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Eosinophilic Esophagitis (EoE) is a serious, chronic disorder that has been increasing in incidence 
and prevalence, and without adequate treatment, is associated with substantial morbidity.  Given the lack 
of consensus on best practice for treating EoE, the invasiveness and potential side effects of current 
treatments, as well as the likelihood of recurrence of symptoms after discontinuing treatment, we propose 
a pilot study to explore a novel treatment approach for EoE in the pediatric population. No studies have 
been published on the efficacy of combining the 2 most common maintenance treatments, swallowed 
steroids and an elimination diet. In a cohort study with 38 newly diagnosed patients, this treatment 
protocol combines and simplifies steroid and diet therapy. Patients will be treated on dedicated clinic days 
by the pediatric gastroenterologist and dietitian in Wake Forest Baptist’s pediatric GI program designed to 
provide continuity of care and ongoing education and support to our patients and families of patients 
living with allergic digestive disorders. The therapy initially combines swallowed steroids and a 2-food 
elimination diet (dairy and soy) for 3 months to relieve symptoms, then alternates treatment with only 2-
food elimination for 3 months, then only steroids for 3 months. Patients will undergo endoscopies 3 times 
throughout treatment after diagnosis to monitor resolution of symptoms over 9 months. We hypothesize 
that a study on this approach will demonstrate resolution of clinical symptoms, histological improvement, 
strong adherence to treatment, and increased quality of life while decreasing the potential for harmful side 
effects of treatments and the burden of an extensive elimination diet.  
 
Specific aim  
1) To determine the degree of efficacy of combining and alternating swallowed steroids and elimination 
of milk and soy from the diet in treatment of pediatric EoE for comparison to single use therapies (dietary 
therapy OR pharmacologic therapy) in a larger multicenter study in the future. 
 
Background/significance 
Eosinophilic Esophagitis (EoE) is a chronic, immune/antigen-mediated clinicopathic disorder that is 
associated with substantial morbidity when left untreated1,2. Multiple treatment options are in place and 
demonstrate effectiveness in achieving clinical and histological remission, but they also include 
considerable drawbacks in terms of patient burden through extensive diet elimination and possible long-
term medication side effects, particularly for children2,3,4. Challenges also exist with difficulty in 
adherence to treatments. In a study of treatment adherence for 96 children with EoE or eosinophilic 
gastroenteritis, non-adherence rates ranged from 30-33%.5 Currently, treatments include elimination and 
elemental diets to decrease allergen exposure, topical glucocorticoids to reduce esophageal inflammation, 
and esophageal dilation for advanced cases with strictures.2,4,6,7 
 
While some physicians consistently utilize allergy testing to direct dietary restrictions, current studies 
suggest that this costly testing may not accurately predict food triggers for EoE, particularly for dairy, the 
most common EoE allergen42. Rather, recent research suggests that elimination of just a few foods may 
effectively alleviate symptoms for most people4,8–11 Multiple studies point to milk as the most common 
trigger, demonstrated as being 8 times more likely to cause EoE as the next most common food in a study 
by Kagalwalla et al9. Soy is currently considered to be another of the top allergens contributing to 
EoE.6,9,10,12 Soy as a top trigger for EoE is further supported by the cross-reactivity between soy protein 
and bovine casein.13–16 Some studies suggest that between 10-14% of people with cow’s milk allergy also 
present with soy protein allergy.15 The combination of research on specific foods triggering EoE 
alongside soy-milk protein cross-reactivity presents a compelling case for consideration of milk and soy 
as preliminary exclusions for an elimination diet to treat EoE. 
 
Swallowed steroids are the most commonly used form of treatment for EoE, and are considered a first line 
approach.2,6,7  As patients often present with EoE after severe morbidity such as food impaction, 
preventing subsequent impactions is the first priority.  In order to resolve symptoms as quickly as possible, 
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initial use of swallowed steroids is indicated.7 As the disease recurs when the steroid is discontinued, 
cyclical use in combination with diet therapy could prevent such recurrence.  However, some families 
choose pharmacological treatment as a preferable lifestyle choice.  Elimination diets and an elemental diet 
require sizeable alterations in daily living and have the potential to strongly impact quality of life2,17,18.  
For some individuals, daily medication is a more feasible option for likely compliance. 
 
Research efforts are increasing to try to reduce the number of foods eliminated empirically, but no studies 
are currently published that demonstrate the effectiveness of combining and alternating pharmacologic 
and dietary treatment4,6,10,11,19. This approach has the potential to increase efficacy of treatment and time 
to remission while decreasing the invasiveness and side effects of current treatments. Additionally, EGDs 
as often as once per month may be used to track progression of symptoms in conjunction with directed 
food elimination and reintroduction. These frequent procedures are both costly and invasive20. As for 
steroid treatment, there is emerging evidence of possible adverse effects of prolonged use, especially in 
children2. This proposed treatment approach reduces expensive, invasive procedures, liberalizes the diet 
to only eliminate the most common triggers to maximize compliance and minimize symptoms, and 
reduces steroids after symptoms begin to resolve. 
 
As a new treatment approach, more substantial data is needed to validate a combined approach and 
explore the parameters of its use.  The data from this pilot study will serve as support for a larger, 
multicenter, prospective study comparing this approach to singular use of dietary restriction or swallowed 
steroids. Further research is needed in this area to establish an optimal treatment strategy for EoE that has 
potential to improve symptoms, minimize burden of treatment, and achieve histological remission to 
ultimately prevent long-term development of esophageal strictures. 
 
Our treatment team consists of two members of Carolinas’ EoE Collaborative, a practice group that aims 
to facilitate collaboration of health care providers with expertise in EoE practicing within the Carolinas to 
provide multi-disciplinary care, education, and research opportunities for those living with EoE. This 
team of collaborators consists of gastroenterologists, allergists and dietitians focused on providing 
evidence based care. As members of this group, Wake Forest has an established forum for advancing and 
sharing treatment advances in academic and clinical settings, and with more substantial pilot data, will be 
ready to collaborate in forming a larger, comprehensive study.  
Preliminary Data 
We conducted a retrospective analysis of new EoE patients at the Wake Forest Baptist pediatric GI clinic 
who have been treated with a combination diet/pharmacologic therapy over the past year.  Of a case group 
of 16 patients who had results from at least 2 endoscopies, 82% of patients who adhered consistently to 
the protocol (11 individuals) achieved histological remission (<15 eosinophils/high powered field), and 
91% demonstrated substantial improvement in number of eosinophils. 31% (5 individuals) had issues 
with compliance to diet or medication, but we believe this can be improved by more support from a 
dietitian and with targeted education materials. This preliminary data confirms the necessity for further 
research on a simplified, combined treatment approach. 
Research Plan  
Study design: We will conduct a prospective cohort study of newly diagnosed pediatric EoE patients 
treated with a combination protocol of swallowed steroids and dietary elimination of milk and soy. 
 
Study setting: This study will take place in the pediatric GI clinic of Wake Forest Baptist Health. Last 
year, we created a program within our clinic designed to provide continuity and ongoing education and 
support to our patients and families of patients living with allergic digestive disorders. As such, we have 
dedicated clinic days for both the physician and dietitian specifically working with these patients.  
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Selection of cases: 38 cases will be enrolled in the study from pediatric patients referred to Wake Forest 
Baptist Health Pediatric GI.  Cases will be newly diagnosed EoE patients between 1 and 21 years of age 
who feed orally and have no past medical history of IBD, Celiac disease, or other EGIDS. Individuals 
who are already on treatment at time of referral will be excluded. Inclusion in the study will be based on 
the clinical and histological guidelines for diagnosis of EoE following standard endoscopy protocol after a 
6-week course of PPIs, ruling out PPI responsive EoE2.  Per standard protocol, secured samples will be 
sent to the pathology lab at Wake Forest Hospital following institution guidelines.  Pathology reports with 
diagnosis suggestion will be generated in the lab and documented in the electronic medical record and 
available to all clinical providers.   
 
Experimental approach: After the diagnostic esophagogastroduodenoscopy (EGD), all visits will take 
place in the pediatric GI outpatient clinic of Wake Forest Baptist Health. 
 
Visit #0: Diagnostic EGD 
Visit #1: The patient and family will complete the study consent form and fill out the initial validated 
Pediatric EoE QOL survey18 and QL EoE Symptoms Scales symptom score index21. 
The patient and family will meet with the gastroenterologist and dietitian to discuss diagnosis, 
medications, and diet therapy.  Patients will receive education and education material packet from the 
dietitian.  Blood draw for vitamin D levels. * 
Visit #2: EGD within 3-4 months 
Visit #3 (3 months + 1 week): Clinic follow-up with gastroenterologist and dietitian.  Assess compliance 
to diet and meds and discuss results from EGD.  Document symptom report. Instruct patient on removing 
medication and continuing diet. 
Visit #4 (6 months): EGD  
Visit #5 (6 months +1 week): Clinic follow-up with gastroenterologist and dietitian. Assess compliance to 
diet and discuss results from EGD.  Document symptom report. Instruct patient on restarting medication 
and liberalizing diet.  
Visit #6 (9 months): EGD 
Visit #7: (9 months + 1 week) Assess compliance to diet and discuss results from EGD.  Document 
symptom report. The patient and family will fill out the final pediatric EoE QOL survey and symptom 
score index. Blood draw for vitamin D levels. 
*Vitamin D levels will be monitored throughout the study to ensure nutritional deficiencies do not occur 
with periodic elimination of dairy and soy products. 
 
Patients will receive an automated reminder one week prior to each of their scheduled appointment to 
mitigate loss to follow-up (LTF).  If the patient misses an appointment, they will receive an email the 
same day prompting the parent to call and reschedule.  If there is no response within 1 week, the study 
coordinator will call and attempt to reschedule.  If there is no response after 1 more week, a second phone 
Table 1: Metrics to be measured 
Metric Method of Collection Time of Collection 
Symptoms Patient and parent report through EoE 
symptom scales21 
Visits #1, #3, #5, #6 
Normal/abnormal EGD Endoscopic findings Visits #0, #2, #4, #6 
Number of eosinophils Pathology report from EGD Visits #0, #2, #4, #6 
QOL Validated EoE pediatric QOL 
survey19  
Visits #1, #7 
Vitamin D* Blood draw Visits #1, #7 
Adherence to treatment Self report  Visits #1, #3, #5, #7 
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call will be placed.  Study participants will also receive incentives in the form of free parking for their 
appointments at the hospital and a small gift card upon completing the study. If we continue with the rate 
of new EoE patient acquisition that we have had in the last year, we anticipate enrolling 38 new patients 
over 9 months, leaving 9 months for participation in the study. Based on current no-show rates for EoE 
patients in the Wake Forest Baptist Health pediatric GI clinic, we predict a maximum 15% overall (LTF) 
for this study.  With this enrollment and rate of LTF, the final study population should be at least 32 





Expected Outcomes and Future Directions 
We hypothesize that this treatment approach will yield substantial improvement in clinical symptoms and 
quality of life, and allow a majority of our patients to achieve histological remission.2 If patients are non-
compliant with the study protocol, they will be removed from the study population while their care 
continues. If the participants are not showing the expected improvement, the dietitian and doctor will 
work with them outside of the study protocol and they will be asked to follow a more extensive 6-food 
elimination diet and reintroduce foods one at a time.19 If this study does not yield the expected 
improvement of symptoms and histological markers, we will be able to determine that this combination of 
treatment is not effective and make changes to improve the treatment protocol. If it is effective, as 
hypothesized and suggested by limited preliminary data, we will collaborate with other centers in the 
Carolina’s to conduct a prospective multicenter study comparing the combined protocol to singular 
treatment protocols using the same measures in order to optimize treatment and quality of life of children 
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Budget Justification  
 
Direct Costs  
a.    Personnel:  
 
Dietitian/Study Coordinator: This will be a part-time position at 9% FTE (3.6 hours per week) for the 
duration of the 18 month study. The coordinator should have a Registered Dietitian (RD) certification in 
order be familiar with stipulations of a diet therapy study and be capable of implementing the protocol 
and counseling patients with minimal supervision. The dietitian will perform medical nutrition therapy, 
which may include nutrient analysis and education, as well as prepare study protocols, obtain data 
collection tools, develop standardized diet education materials, and coordinate with individuals from 
epidemiology, pathology, pediatric GI, and UNC pediatric GI. 
 
Year 1: $50,000/12 months x 9%= $4,568 + 16% fringe benefits of $731 = $5,299  
Year 2: $50,000/6 months x 9% = $2,284 + 16% fringe benefits of $365 = $2,649  
   
Total for all personnel: $7,948 
 
 b.    Supplies 
 
-Printing for education materials: 38 packets x $1.30 per color page x 6 pages = $296 
 
Total for supplies: $296 
 
 c.    Incentives:  
 
As incentive for participation in the study and timely appointment follow-up, patients will receive free 
parking in the Wake Forest Baptist visitors lot for each of their (7) study visits.  At the completion of their 
participation in the study (7 appointments), individuals will receive a $20 Visa gift card. 
 
-Parking at each visit: $4.50 x 32 participants for full study x 7 visits = $1,008 
       $4.50 x 6 participants presumed LTF x 4 visits = $108 
-At visit #7: $20 Visa gift card x 30 participants =$640 
 
            Total for incentives: $1,756 
 


















    Fringe YEAR 02   
PERSONNEL Role Base 0.16  Effort Salary Fringe Total Effort Salary Fringe Total 
2 Year 
Total 
Safta, Anca PI       0  0  0    0  0  0  0 
Jensen, Elizabeth Co-investigator     0 0  0   0 0  0 0  
Total Key Personnel:       0  0  0    0  0  0  0 
To Be Named 
Clinical 
Dietitian/Study 
Coordinator 50,000 $8,000.00  9% 4,568  731  5,299  4.5% 2,284  365  2,649  7,948 
TOTAL 





page             
Education 
materials (color 
printing) 38 6 1.30     296    0  0  296 
Other (Incentives) Participants Appointments 
Cost per 
visit     Participants Appointments 
Cost per 
visit    
Parking (full 
participants) 32  5 4.50    720  32 2  4.50  288  1,008 
Parking (LTF 
participants) 6  4 4.50    108     0  0  108 
Gift Card       0  32  20 640  640 
Total Non-
Personnel:       1,124     928 2,052 
TOTAL DIRECT 
Costs:       $6,423      $3,577  $10,000 
